HRP20190907T1 - Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) - Google Patents

Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) Download PDF

Info

Publication number
HRP20190907T1
HRP20190907T1 HRP20190907TT HRP20190907T HRP20190907T1 HR P20190907 T1 HRP20190907 T1 HR P20190907T1 HR P20190907T T HRP20190907T T HR P20190907TT HR P20190907 T HRP20190907 T HR P20190907T HR P20190907 T1 HRP20190907 T1 HR P20190907T1
Authority
HR
Croatia
Prior art keywords
mutant
leukocidin
subunit
tag
seq
Prior art date
Application number
HRP20190907TT
Other languages
English (en)
Croatian (hr)
Inventor
Mohammad Javad Aman
Rajan Prasad ADHIKARI
Hatice KARAUZUM
Jawad Sarwar
Sergey Shulenin
Sathya VENKATARAMANI
Kelly Lyn Warfield
Tam Luong NGUYEN
Original Assignee
Integrated Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrated Biotherapeutics, Inc. filed Critical Integrated Biotherapeutics, Inc.
Publication of HRP20190907T1 publication Critical patent/HRP20190907T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190907TT 2011-12-02 2012-11-30 Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) HRP20190907T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566234P 2011-12-02 2011-12-02
PCT/US2012/067483 WO2013082558A1 (en) 2011-12-02 2012-11-30 Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
EP12854165.3A EP2785368B1 (en) 2011-12-02 2012-11-30 Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Publications (1)

Publication Number Publication Date
HRP20190907T1 true HRP20190907T1 (hr) 2019-07-12

Family

ID=48536149

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190907TT HRP20190907T1 (hr) 2011-12-02 2012-11-30 Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl)

Country Status (13)

Country Link
US (1) US10023848B2 (cg-RX-API-DMAC7.html)
EP (1) EP2785368B1 (cg-RX-API-DMAC7.html)
JP (1) JP6325452B2 (cg-RX-API-DMAC7.html)
KR (1) KR101999299B1 (cg-RX-API-DMAC7.html)
AU (1) AU2012345645B2 (cg-RX-API-DMAC7.html)
CA (1) CA2857666C (cg-RX-API-DMAC7.html)
DK (1) DK2785368T3 (cg-RX-API-DMAC7.html)
ES (1) ES2728445T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190907T1 (cg-RX-API-DMAC7.html)
LT (1) LT2785368T (cg-RX-API-DMAC7.html)
RS (1) RS58919B1 (cg-RX-API-DMAC7.html)
SI (1) SI2785368T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013082558A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2785368B1 (en) 2011-12-02 2019-03-13 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
EP3441474B1 (en) * 2013-06-18 2020-07-22 New York University Pharmaceutical compositions containing a mutated leukocidin e
PT3010535T (pt) 2013-06-19 2020-07-03 Integrated Biotherapeutics Inc Péptidos de toxoide derivados de modulina solúvel em fenol, delta toxina, superantigénios e suas fusões
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
RU2016119052A3 (en) * 2013-10-17 2018-09-10 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody sequences
WO2017026301A1 (ja) * 2015-08-10 2017-02-16 株式会社微生物化学研究所 黄色ブドウ球菌不活化菌体とロイコシジンを混合したワクチン
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
US11260120B2 (en) 2017-07-27 2022-03-01 Integrated Biotherapeutic Vaccines, Inc. Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
WO2025085539A1 (en) * 2023-10-16 2025-04-24 The Trustees Of Columbia University In The City Of New York Engineered bacteria for cellular barrier maintenance and protection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20100158871A1 (en) 1999-08-30 2010-06-24 David Stephen Terman Sickled erythrocytes with antitumor molecules induce tumoricidal effects
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
TWI374892B (en) * 2005-06-13 2012-10-21 Glaxosmithkline Biolog Sa Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
AU2007310738B2 (en) * 2006-10-18 2013-07-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for in vitro diagnosis of PVL-producing Staphylococcus aureus
EP2785368B1 (en) 2011-12-02 2019-03-13 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Also Published As

Publication number Publication date
US20140308291A1 (en) 2014-10-16
AU2012345645B2 (en) 2017-09-07
KR20140117381A (ko) 2014-10-07
CA2857666A1 (en) 2013-06-06
EP2785368A1 (en) 2014-10-08
NZ626762A (en) 2016-07-29
RS58919B1 (sr) 2019-08-30
US10023848B2 (en) 2018-07-17
AU2012345645A1 (en) 2014-06-26
SI2785368T1 (sl) 2019-08-30
ES2728445T3 (es) 2019-10-24
JP2015505831A (ja) 2015-02-26
EP2785368B1 (en) 2019-03-13
WO2013082558A1 (en) 2013-06-06
DK2785368T3 (da) 2019-05-27
JP6325452B2 (ja) 2018-05-16
LT2785368T (lt) 2019-06-10
EP2785368A4 (en) 2015-12-30
KR101999299B1 (ko) 2019-07-12
CA2857666C (en) 2020-08-11

Similar Documents

Publication Publication Date Title
HRP20190907T1 (hr) Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl)
DK2445526T3 (en) Recombinant RSV antigens.
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
CA2710600C (en) Recombinant rsv antigens
HRP20191902T1 (hr) Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe
CA2952351C (en) Influenza virus vaccines and uses thereof
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
HRP20170094T1 (hr) Imunogeni pripravak
Yadav et al. Characterization of immune response elicited by the recombinant outer membrane protein OmpF of Aeromonas hydrophila, a potential vaccine candidate in murine model
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
JP2014507146A5 (cg-RX-API-DMAC7.html)
WO2008127179A8 (en) Fusion protein vaccine
US20160122398A1 (en) Recombinant rsv antigens
WO2015107363A3 (en) Mycobacterial antigen composition
Guo et al. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection
KR101919002B1 (ko) 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
CN107344969B (zh) 一种纳米流感疫苗及构建方法和应用
CN104560780B (zh) 产气荚膜梭菌ε毒素减毒突变体及其应用
Zhou et al. A novel multivalent vaccine based on secretary antigen-delivery induces protective immunity against Vibrio anguillarum and Aeromonas hydrophila
WO2013171661A3 (en) Adjuvant formulations and methods
WO2013158061A1 (en) Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
MX2023001219A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus.
Zhou et al. The recombinant vaccine of Lactobacillus plantarum elicits immune protection against H1N1 and H9N2 influenza virus infection
JP2015524420A5 (cg-RX-API-DMAC7.html)